Suppression of leukemia development caused by PTEN loss
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Multiple genetic or molecular alterations are known to be associated with cancer stem cell formation and cancer development. Targeting such alterations, therefore, may lead to cancer prevention. By crossing our previously established phosphatase and tensin homolog (Pten) - null acute T-lymphoblastic leukemia (T-ALL) model onto the recombination-activating gene 1 −/− background, we show that the lack of variable, diversity and joining [V(D)J] recombination completely abolishes the Tcrα/δ-c-myc translocation and T-ALL development, regardless of β-catenin activation. We identify mammalian target of rapamycin (mTOR) as a regulator of β-selection. Rapamycin, an mTOR-specific inhibitor, alters nutrient sensing and blocks T-cell differentiation from CD4 − CD8 − to CD4 + CD8 + , the stage where the Tcrα/δ-c-myc translocation occurs. Long-term rapamycin treatment of preleukemic Pten -null mice prevents Tcrα/δ-c-myc translocation and leukemia stem cell (LSC) formation, and it halts T-ALL development. However, rapamycin alone fails to inhibit mTOR signaling in the c-Kit mid CD3 + Lin − population enriched for LSCs and eliminate these cells. Our results support the idea that preventing LSC formation and selectively targeting LSCs are promising approaches for antileukemia therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“Of course, we cannot rule out the possible acquisition of drug-resistant mutations (34) most notably shown by characterization of Gleevec resistance in human chronic myelogenous leukemia (35).”
BackgroundWilson, A., Laurenti, E., Oser, G., van der Wath, R. C., Blanco-Bose, W., Jaworski, M., Offner, S., Dunant, C. F., Eshkind, L., Bockamp, E., et al. (2008) · Cell · doi:10.1016/j.cell.2008.10.048 · Cited by 1,908
Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C., et al. (2009) · Cell · doi:10.1016/j.cell.2008.11.044 · Cited by 1,798
IFNα activates dormant haematopoietic stem cells in vivo
Essers, M. A. G., Offner, S., Blanco-Bose, W. E., Waibler, Z., Kalinke, U., Duchosal, M. A., & Trumpp, A. (2009) · Nature · doi:10.1038/nature07815 · Cited by 1,368
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention
Zhang, J., Grindley, J. C., Yin, T., Jayasinghe, S., He, X. C., Ross, J. T., Haug, J. S., Rupp, D., Porter-Westpfahl, K. S., Wiedemann, L. M., et al. (2006) · Nature · doi:10.1038/nature04747 · Cited by 817 · cited 2×
“The absence of myeloid leukemia in both Pten null and Pten;Rag1 null mice suggests that the AML phenotype observed in Pten;Mx-1Cre mice may result from a higher proportion of hematopoietic stem cells (HSCs) carrying Pten deletion (14, 16), a nichedependent effect (15, 17), and/or effects of pIpC and pIpCinduced IFN ac…”
BackgroundResultSelf-citationRb Regulates Interactions between Hematopoietic Stem Cells and Their Bone Marrow Microenvironment
Walkley, C. R., Shea, J. M., Sims, N. A., Purton, L. E., & Orkin, S. H. (2007) · Cell · doi:10.1016/j.cell.2007.03.055 · Cited by 424 · cited 1×
“The absence of myeloid leukemia in both Pten null and Pten;Rag1 null mice suggests that the AML phenotype observed in Pten;Mx-1Cre mice may result from a higher proportion of hematopoietic stem cells (HSCs) carrying Pten deletion (14, 16), a nichedependent effect (15, 17), and/or effects of pIpC and pIpCinduced IFN ac…”
BackgroundChromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers
Maser, R. S., Choudhury, B., Campbell, P. J., Feng, B., Wong, K.-K., Protopopov, A., O’Neil, J., Gutierrez, A., Ivanova, E., Perna, I., et al. (2007) · Nature · doi:10.1038/nature05886 · Cited by 377
Taghon, T., Yui, M. A., Pant, R., Diamond, R. A., & Rothenberg, E. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.012 · Cited by 312
Critical roles of the PI3K/Akt signaling pathway in T cell development
Juntilla, M. M., & Koretzky, G. A. (2008) · Immunology Letters · doi:10.1016/j.imlet.2007.12.008 · Cited by 147
Cited by
Regulation and function of mTOR signalling in T cell fate decisions
Chi, H. (2012) · Nature Reviews Immunology · doi:10.1038/nri3198 · Cited by 1,035
PTEN Tumor-Suppressor: The Dam of Stemness in Cancer
Luongo, F., Colonna, F., Calapà, F., Vitale, S., Fiori, M. E., & De Maria, R. (2019) · Cancers · doi:10.3390/cancers11081076 · Cited by 189
“Consistently, PTEN expression induces cell cycle arrest in BCR-ABL expressing leukemia cells [142,144,159,160].”
BackgroundmTOR Signaling, Tregs and Immune Modulation
Chapman, N. M., & Chi, H. (2014) · Immunotherapy · doi:10.2217/imt.14.84 · Cited by 148
PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis
He, J., Zhang, Z., Ouyang, M., Yang, F., Hao, H., Lamb, K. L., Yang, J., Yin, Y., & Shen, W. H. (2016) · Nature Communications · doi:10.1038/ncomms12355 · Cited by 58
PTEN regulates PLK1 and controls chromosomal stability during cell division
Zhang, Z., Hou, S.-Q., He, J., Gu, T., Yin, Y., & Shen, W. H. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1203493 · Cited by 46
Metadata
- Authors
- Guo, W., Schubbert, S., Chen, J. Y., Valamehr, B., Mosessian, S., Shi, H., Dang, N. H., Garcia, C., Theodoro, M. F., Varella-Garcia, M., & Wu, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-01-06
- Volume
- 108
- Issue
- 4
- Pages
- 1409-1414
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2113136321
- Cited by
- 70
- References
- 9
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suppression of leukemia development caused by PTEN loss. https://app.cochat.ai/papers/10.1073/pnas.1006937108
- The paper
- Guo, W., Schubbert, S., Chen, J. Y., Valamehr, B., Mosessian, S., Shi, H., Dang, N. H., Garcia, C., Theodoro, M. F., Varella-Garcia, M., & Wu, H. (2011). Suppression of leukemia development caused by PTEN loss. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1006937108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.